STTK vs. VRCA, KRRO, NGNE, ESPR, MREO, TERN, HRTX, ANRO, ORGO, and AMRN
Should you be buying Shattuck Labs stock or one of its competitors? The main competitors of Shattuck Labs include Verrica Pharmaceuticals (VRCA), Korro Bio (KRRO), Neurogene (NGNE), Esperion Therapeutics (ESPR), Mereo BioPharma Group (MREO), Terns Pharmaceuticals (TERN), Heron Therapeutics (HRTX), Alto Neuroscience (ANRO), Organogenesis (ORGO), and Amarin (AMRN). These companies are all part of the "pharmaceutical preparations" industry.
Shattuck Labs (NASDAQ:STTK) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.
58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 10.5% of Shattuck Labs shares are held by company insiders. Comparatively, 42.6% of Verrica Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Verrica Pharmaceuticals received 134 more outperform votes than Shattuck Labs when rated by MarketBeat users. However, 76.32% of users gave Shattuck Labs an outperform vote while only 64.94% of users gave Verrica Pharmaceuticals an outperform vote.
Verrica Pharmaceuticals has higher revenue and earnings than Shattuck Labs. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.
Verrica Pharmaceuticals has a net margin of -905.83% compared to Shattuck Labs' net margin of -3,133.63%. Shattuck Labs' return on equity of -64.85% beat Verrica Pharmaceuticals' return on equity.
In the previous week, Verrica Pharmaceuticals had 5 more articles in the media than Shattuck Labs. MarketBeat recorded 16 mentions for Verrica Pharmaceuticals and 11 mentions for Shattuck Labs. Verrica Pharmaceuticals' average media sentiment score of 0.46 beat Shattuck Labs' score of 0.39 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.
Shattuck Labs currently has a consensus target price of $20.00, suggesting a potential upside of 152.68%. Verrica Pharmaceuticals has a consensus target price of $13.50, suggesting a potential upside of 55.71%. Given Shattuck Labs' higher probable upside, equities analysts clearly believe Shattuck Labs is more favorable than Verrica Pharmaceuticals.
Shattuck Labs has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500.
Summary
Verrica Pharmaceuticals beats Shattuck Labs on 9 of the 17 factors compared between the two stocks.
Get Shattuck Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for STTK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Shattuck Labs Competitors List
Related Companies and Tools
